RecruitingPhase 2NCT06921213
Comprehensive Ambulatory Antibiotics for the Treatment of Congenital Syphilis
Sponsor
London School of Hygiene and Tropical Medicine
Enrollment
90 participants
Start Date
May 4, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
CARES-1 is a randomised, open-label, phase II pharmacokinetic (PK) and safety study of ambulatory antibiotics for the treatment of neonates with "all-risk" asymptomatic congenital syphilis.
Eligibility
Min Age: 0 DaysMax Age: 7 Days
Inclusion Criteria10
- Infants at risk of congenital syphilis at birth defined as:
- an infant born to a mother who tests positive for syphilis in pregnancy using registered and licensed locally-available diagnostic tests for example but not limited to a Treponemal rapid POCT, an RPR or both.
- AND
- the mother is untreated in the current pregnancy defined as:
- i. she tested positive at antenatal care and received no treatment OR ii. she was never tested during antenatal care OR iii. she tested negative at antenatal care and positive on re-testing at delivery
- OR c. the mother is inadequately treated in the current pregnancy defined as:
- i. Having received a non-penicillin based treatment regimen; and/or ii. Does not have documentation of 3 doses of IM Benzathine Penicillin, given 7-10 days apart, with the last dose given > 30 days prior to delivery OR b. The mother was adequately treated in the current pregnancy BUT considers herself at risk of re-infection following a midwife delivered explanation of risk (partner treatment, multiple partners etc).
- Infants who are asymptomatic for a diagnosis of congenital syphilis following application of a clinical proforma by the study team (Appendix 1)
- Infants who are less than <= 7 days of life AND with a post-menstrual age (PMA) of 34-42 weeks (Appendix 2).
- Infants who are tolerating enteral feeds, including if they are being administered by an NG tube.
Exclusion Criteria2
- \- 1. The infant's clinical condition at birth or prior to randomisation requires ongoing (> 48 hours) treatment with antibiotics with the potential for anti-treponemal activity i.e. B-lactams, Cephalosporins, Carbapenems.
- \. They have a birthweight <2kg 3. They are nil by mouth. 4. They have a life-limiting congenital anomaly
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGLinezolid (LZD)
Ten day course. Oral Linezolid dosed at 10mg/kg twice a day.
DRUGAmoxicillin
Ten day course. Oral Linezolid dosed at 50mg/kg twice a day.
DRUGBenzathine Penicillin G
Single IM dose 50,000iu/kg
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06921213